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Background:  Enzyme  immunoassays  (EIA)  designed  to  detect  hepatitis  C virus  (HCV)  core  antigen  and
anti-HCV  antibodies  (HCV  AgAb)  simultaneously  can improve  the  early  detection  of HCV  infection  when
molecular  diagnostic  methods  are  not  widely  available.
Objectives:  To  evaluate  the  suitability  of  dried  blood  spot  (DBS)  samples  for  detecting  HCV  AgAb  using
commercial  EIAs.
Study design:  Paired  serum  and  DBS  samples  were  assayed  using  two  commercial  EIAs for  HCV  AgAb
(MonolisaTM HCV  AgAb  ULTRA  and  Murex  HCV  AgAb).  Manufacturer’s  recommendations  were  followed
for sera  while  sample  volume,  incubation  time  and  cut-off  (CO)  determination  were  evaluated  for  the
DBS  samples.  The  values  of  sensitivity,  speciﬁcity,  inter-rater  agreement,  detection  limit, assay  precision
and stability  of  DBS  samples  at  different  conditions  (22–26 ◦C,  2–8 ◦C  and  −20 ◦C)  were  determined.
Results:  It  was  necessary  to increase  the  DBS  sample  volume  fourfold  compared  to  the  sera  samples  to
approximate  the  DBS  Optical  Density  (OD)  values  to  the  sera  OD  values.  Using  ROC  curve  to  recalculate
CO values  for  the  DBS  samples,  sensitivity  was  97.5%  for both  EIAs,  while  the  speciﬁcity  was  99.71%  for
MonolisaTM HCV  AgAb  ULTRA  and  95.95%  for Murex  HCV AgAb.  Accurate  testing  results  were  obtained
◦with  DBS  samples  for 60  days  at  all conditions  evaluated;  storage  at  −20 C resulted  in  low  OD  variation.
Both  EIAs  demonstrated  the  same  limit  of  detection  among  DBS  samples  [estimated  viral  load  of  3.1
International  Units  per millilitre  (IU/mL)]  and  low  OD  value  variability  in  repetitivity  and  reproducibility
studies.
Conclusion:  DBS  samples  can  be used  for the  detection  of  HCV  AgAb  by  EIA  as  they  present  comparable
ics  anperformance  characterist
. Background
Hepatitis C virus (HCV) infection can be diagnosed by the pres-
nce of antigen, antibody or viral genome among sera or plasma
amples. Three generations of enzyme immunoassays (EIAs) for
ntibodies against HCV (anti-HCV) have been developed that
ncreased sensitivities from 80% among ﬁrst generation ELISAs to
8% among third generation ELISAs and that reduced the window
eriod from 82 to 66 days.1,2 Assays for the simultaneous detection
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Open access under the Elsevier OA license.d  excellent  stability  among  various  storage  conditions.
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of anti-HCV and HCV core antigen (HCV AgAb) have been devel-
oped. These new assays have advantages over conventional assays,
including a sensitivity of 100% and a speciﬁcity of 99.5%, which
allows for earlier diagnosis, especially in immunocompromised
patients.3,4
In Brazil, the prevalence of HCV varies from 1.12% to 1.64%, and
the highest occurrence rates have been observed in the northern
region of Brazil.5 Brazil is a large country, and some areas, espe-
cially the regions with the highest HCV occurrence, are far from
specialised laboratories. Accordingly, the use of dried blood spots
(DBS) would be advantageous over conventional blood sampling
because this method would allow for the collection and trans-
Open access under the Elsevier OA license.portation of samples from remote areas to reference laboratories.
Currently, DBS samples have been used for anti-HCV and HCV RNA
detection,6–14 but no study has reported the simultaneous detec-
tion of HCV antigen and antibodies in DBS.
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. Objective
The objectives of this study were to evaluate the possibility of
imultaneous detection of anti-HCV and HCV core antigen in DBS
sing commercial ELISA kits and to assess the stability of DBS stored
t diverse conditions (22–26 ◦C, 2–8 ◦C and −20 ◦C).
. Study design
.1. Population
In this study, 386 individuals were included. Of the study par-
icipants, 40 subjects were anti-HCV/HCV RNA reactive and were
eferred from viral hepatitis centres in Rio de Janeiro. A total of
46 subjects were anti-HCV/HCV RNA negative and had donated
lood samples at two hospitals in Rio de Janeiro (Unimed Hospi-
al and Federal Hospital, from the Servers of the State of Rio de
aneiro – HFSE). The samples were collected from January 2009 to
arch 2010, and the study was approved by the ethics commit-
ees of Fiocruz and HFSE. Most of the study subjects were female
56.2%), and the mean age was 40 years, with the ages ranging from
1 to 60 years.
.2. Sample collection and preparation
Venous blood was collected into Vacutainer tubes (BD, San Jose,
A, USA). One aliquot of blood was centrifuged to obtain the sera,
hile 75 L of whole blood was inoculated onto Whatman ﬁlter
aper n◦903 (GE Healthcare, Piscataway, NJ, USA).
Alternatively, 3–5 drops of capillary blood obtained by a ﬁnger
rick were inoculated onto the same type of ﬁlter paper. The DBS
amples were air-dried at room temperature for 4 h, placed in indi-
idual sealable plastic bags containing silica desiccant sachets and
tored at −20 ◦C.
A 3 mm disc was punched from each DBS sample and placed into
icrotubes containing 300 L of buffer PBS/BSA 0.5% at 4–8 ◦C for
8–24 h. The blood was then eluted from the paper as described
reviously.14,15
.3. Enzyme immunoassays
Two enzyme immunoassays were used: the MonolisaTM HCV
gAb ULTRA, Bio-Rad (Marnes-la-Coquette, France), and Murex
CV AgAb, Abbott (Kyalami, Republic of South Africa). The assays
etected the HCV antigen and the antibody simultaneously. The
era samples were tested according to the manufacturer’s recom-
endations, with 50 L of sera used for the EIAs. For the Murex
CV AgAb assay, 50 L of specimen diluent was used. For the DBS
ample, a preliminary panel of ten subjects (5 positive for HCV AgAb
nd 5 negative for HCV AgAb) donated paired sera and DBS sam-
les to determine the initial DBS sample volume without specimen
iluents (50 L, 100 L, 150 L, 200 L) and the sample incubation
ime (determined by the manufacturer, with 90 minutes used for
he Bio-Rad assay and 60 min  used for the Abbott assay, and twofold
ncreasing periods of time).
After establishing these parameters, the cut-off (CO) absorbance
alues for the DBS specimens were calculated by three methods
sing the entire population that was studied (n = 386). CO1 was
eﬁned using the manufacturer’s recommendations, and CO2 was
eﬁned as 3 standard deviations above the mean DBS absorbance
f the HCV seronegative samples (mean + 3 SD). CO3 was the area
nder the receiver operating characteristic curve (AUROC),16,17
hich was created using MedCalc statistical software (version
.2.1.0, MedCalc Software, Belgium).cal Virology 57 (2013) 98– 102 99
3.4. Determination of the limit of detection, precision and
stability of HCV AgAb using DBS
HCV AgAb reactive sera samples (OD values above 3.0 in both
EIAs and a viral load equal to 3100 International Units per millil-
itre (IU/mL)) were serially diluted tenfold in negative whole blood
samples (dilution series from 1:10 to 1:1010), and this dilution was
serially inoculated (75 L) onto Whatman 903 paper. This panel
was  processed as described in Section 3.2 and tested using the two
EIAs after optimisation to determine the limit of detection. The cap-
illary whole blood was  obtained by digital punch, and the procedure
described above was  performed.
The HCV AgAb DBS reactive samples (dilutions 1:10 and 1:1000)
were tested 8 times in a single run using both EIAs, and the mean,
standard deviation, and coefﬁcient of variation (CV) among the
replicates were obtained to determine the precision of the EIAs.
Repetitivity was  determined by testing a sample 20 times in the
same run, with a single technician using the same reagents, lot and
operator.18 Reproducibility was obtained by testing identical sam-
ples ten times in a single run on two days using the same lot and
reagents but different operators.18
Stability was  determined using one HCV AgAb reactive DBS sam-
ple and one negative DBS sample that were prepared and processed
as described in Section 3.2. These samples were stored at 20–25 ◦C,
2–8 ◦C and −20 ◦C for 7, 14, 28, 60 and 117 days.19 OD values from
each day were compared to the initial value (day 7) to determine
the recovery of HCV AgAb detection. All assays were performed in
triplicate.
3.5. Statistical analysis
HCV AgAb detection in serum samples was used as the gold
standard for to assess the sensitivity, speciﬁcity, and positive (PPV)
and negative (NPV) predictive values of the DBS HCV AgAb assay.
The descriptive statistics are shown as the mean ± standard devi-
ation or the median and interquartile range, as appropriate. The
categorical variables were compared between groups by the 2 test
or Fisher’s exact test, and noncategorical variables were compared
by the Mann–Whitney U test. A p value of <0.05 was  considered
signiﬁcant. Concordance between results obtained for whole DBS
samples and matched serum samples was established using the
Kappa index. All data analysis was  performed using program 3.01
(GraphPad InStat®software, San Diego, CA) and MedCalc (version
9.2.1.0, MedCalc Software, Belgium).
4. Results
4.1. Optimisation of HCV AgAb EIAs using DBS
Using the preliminary panel, a 4-fold increase in the DBS initial
volume (ﬁnal volume of 200 L) gave more appropriate DBS OD
values compared to the sera OD values (Table 1). A longer period of
DBS sample incubation did not improve the OD values of the DBS
samples (Table 2). The sample incubation time recommended by
the manufacturer (90 min  for the Bio-Rad EIA and 60 min  for the
Abbott EIA) and a 4-fold increased sample volume without diluent
were used.
The CO values were evaluated using the entire population and
higher sensitivities and speciﬁcities were observed using the ROC
curve (CO3) for the Bio-Rad EIA (CO value = 0.287) (Table 3) and the
Abbott EIA (CO value = 0.239) (Table 4).Using a ROC curve, 39 DBS samples of 40 paired HCV AgAb
positive serum specimens were detected by both EIAs, while 1
HCV AgAb false positive was observed for the BioRad EIA, and
14 HCV AgAb false positives were detected using the Abbott EIA.
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Table 1
Mean optical densities (O.D.) obtained from paired sera and dried blood spot (DBS) samples according to the sample volume used in the assay.
Volume (L) Murex HCV AgAb combination EIA (Abbott) MonolisaTM HCV  AgAb ULTRA EIA (Biorad)
Diluent volume (L) Mean O.D. (nm)
Non-reactive sample
Mean O.D. (nm)
Reactive sample
Mean O.D. (nm)
Non-reactive sample
Mean O.D. (nm)
Reactive sample
Sera
50 50 0.133 2.781 0.044 1.842
DBS
50  0 0.105 1.282 0.052 0.634
100  0 0.089 1.359 0.066 0.685
150  0 0.105 1.271 0.080 0.735
200  0 0.086 1.224 0.082 0.892
p-Value 0.135 0.999 0.038 0.791
Table 2
Mean optical densities (O.D.) obtained from paired sera and dried blood spots (DBS) according to different incubation periods.
Sample Murex HCV AgAb combination EIA (Abbott) MonolisaTM HCV AgAb ULTRA EIA (Biorad)
Incubation
time
Mean O.D. (nm)
Non-reactive sample
Mean O.D. (nm)
Reactive sample
Incubation
time
Mean O.D. (nm)
Non-reactive sample
Mean O.D. (nm)
Reactive sample
Sera 60 min  0.133 2.781 90 min  0.044 1.842
DBS  60 min  0.105 1.271 90 min  0.082 0.892
DBS  120 min  0.142 1.462 180 min  0.129 1.192
DBS  18–24 h 0.160 1.035 18–24 h ND* ND*
ND*: not done.
Table 3
Accuracy indices for different methods of cut-off absorbance calculation for HCV AgAb detection with DBS samples (MonolisaTM HCV AgAb ULTRA EIA).
Method Cut-off (nm) Sensitivity (95% IC) Speciﬁcity (95% IC) PPV* (95% IC) NPV* (95% IC) Accuracy (kappa)
CO1 – 95.00% 100% 100% 99.43% 0.971
(83.08–99.39) (98.94–100) (90.75–100) (97.94–99.93) (0.932–1)
CO2  0.108 97.50% 97.19% 79.59% 99.71% 0.860
(86.84–99.94) (94.90–98.64) (65.65–89.76) (98.41–99) (0.860–1)
CO3  0.287 97.50% 99.71% 100% 99.97% 0.986
(86.84–99.94) (98.40–99.99) (90.97–100) (98.98–100) (0.934–1)
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xcellent agreement among the DBS and sera EIAs was determined
y the Kappa index (k: 0.972 and 0.817, BioRad and Abbott assays,
espectively) (Tables 3 and 4).
.2. Stability studies
During the period of storage under all conditions, all repli-
ates of the HCV DBS positive samples remained ELISA positive
Figs. 1a and 2a), and the replicates of the HCV DBS negative samples
emained negative by the BioRad assay (Fig. 1b). Using the Abbott
ssay, the DBS negative samples were stable until 60 days of storage
Fig. 2b). The lowest OD value variations were observed at −20 ◦C,
uggesting that this temperature is the best storage condition for
BS.
able 4
ccuracy indices for different methods of cut-off absorbance calculations for HCV AgAb d
Method Cut-off (nm) Sensitivity (95% IC) Speciﬁcity (95%
CO1 – 82.50% 97.98% 
(67.22–92.66) (95.88–99.18) 
CO2  0.514 80.00% 99.42% 
(64.32–90.94) (97.93–99.93) 
CO3  0.239 97.50% 95.95% 
(86.84–99.94) (93.30–97.77) 
PV: positive predictive value; NPV: negative predictive value; accuracy: TP + TN/TP + TN
etermined by 3 standard deviations above the mean DBS absorbance of HCV seronegativ
perating characteristic (AUROC) curve analysis for DBS absorbance values. + FP + FN CO1: cut-off value determined by the manufacturer; CO2: cut-off value
e samples (mean + 3 SD); CO3: cut-off value determined by the area under receiver
4.3. Limit of detection
It was  possible to detect HCV AgAb among DBS samples using the
EIAs and optimised protocol at an estimated viral load of 3.1 IU/mL
(dilution 1:103).
Reproducibility was  obtained by having different operators test
the same samples ten times in a single run on two  days, using the
same lot and the same reagents.18
To determine EIA precision, two HCV AgAb reactive DBS sam-
ples (dilution 1:10 and 1:1000) were tested 8 times in a single
run using both EIAs. A high titre of the HCV AgAb DBS sam-
ple (estimated viral load = 310 IU/mL) presented a mean ± SD OD
value of 2.417 ± 0.1 for the Bio-Rad EIA and 2.838 ± 0.335 for
the Abbott EIA. A low titre of the HCV AgAb DBS sample (esti-
mated viral load 3.1 IU/mL) presented a mean ± SD OD value of
etection with DBS samples (Murex HCV AgAb combination EIA).
 IC) PPV* (95% IC) NPV* (95% IC) Accuracy (kappa)
82.50% 97.98% 0.805
(67.22–92.66) (95.87–99.18) (0.706–0.904)
94.12% 97.73% 0.851
(80.32–99.28) (95.58–99.01) (0.693–0.904)
73.58% 99.97% 0.817
(59.72–84.73) (98.34–99.99) (0.728–0.906)
 + FP + FN CO1: cut-off value determined by the manufacturer; CO2: cut-off value
e samples (mean + 3 SD); CO3: cut-off value determined by the area under receiver
C.P.U. Brandão et al. / Journal of Clini
Fig. 1. (a) Stability of reactive HCV Ag–Ab DBS samples obtained during 117-day
period at different storage conditions using EIA HCV AgAb: MonolisaTM HCV Ag–Ab
ULTRA (Bio-Rad, France). Cut off (CO) value as determined by ROC curve method
(0.287 nm). (b) Stability of non-reactive HCV Ag–Ab DBS samples obtained during
117-day period at different storage conditions using EIA HCV AgAb: MonolisaTM
HCV Ag–Ab ULTRA (Bio-Rad, France). Cut off (CO) value as determined by ROC curve
method (0.287 nm).
Fig. 2. (a) Stability of reactive HCV Ag–Ab DBS samples obtained during 117-day
period at different storage conditions using EIA Murex HCV Ag/Ab (Abbott, South
of Africa). Cut off (CO) value as determined by ROC curve method (0.239 nm). (b)
Stability of non reactive anti-HCV DBS samples obtained during 117-day period at
different storage conditions using EIA Murex HCV Ag/Ab (Abbott, South of Africa).
Cut  off value as determined by ROC curve method (0.239 nm).cal Virology 57 (2013) 98– 102 101
0.633 ± 0.049 using the BioRad EIA and 0.508 ± 0.038 with the
Abbott EIA.
For the repetitivity evaluation, high and low titre HCV AgAb DBS
samples were tested 20 times in the same run by a single technician
using the same reagents, lot and operator. No OD value variation
was  observed with the Abbott EIA using a high titre sample, while
the coefﬁcient of variation (CV) of the OD values was 2.8% using
this sample with the BioRad EIA. When the low titre HCV AgAb DBS
sample was  analysed, the CV was  5.0% for the BioRad EIA and 3.5%
for the Abbott EIA. In the reproducibility studies, analyses using
high titre HCV AgAb DBS samples presented a CV of 4.0% for the
BioRad EIA and 6.7% for the Abbott EIA. For the low titre HCV AgAb
DBS sample, the CV was 13.8% for the BioRad EIA and 4.7% for the
Abbott EIA (Table 5).
5. Discussion
In this study, it was  possible to detect HCV AgAb among dried
blood spot samples using commercial EIAs, but some modiﬁca-
tions in the protocol should be made. It was  necessary to increase
the DBS sample volume for HCV AgAb detection, likely due to the
low amount of antigens and antibodies present in these samples as
compared to the sera samples.20 Once the DBS is eluted, the anti-
gens and antibodies are probably reduced in these samples, and by
increasing the DBS elution volume on the ELISA, the efﬁciency of
the method can be improved.11,21–23 The sample incubation time
did not inﬂuence the performance of the assay, as the same as
observed for the anti-HCV and HBV markers detection among the
DBS samples.14,15
Another factor that was evaluated was  the cut-off determina-
tion, in which the ROC curve gave the highest sensitivities and
speciﬁcities for HCV AgAb detection using both EIAs, which was
similar to results demonstrated for the detection of HBV and anti-
HCV in the DBS samples.14,15 The Biorad EIA performed the best
because the sensitivities and speciﬁcities were higher than 95%
using the cut-off established by the manufacturer. All accuracy
indices had good performance, except for the positive predictive
values for the Biorad assay using the CO2 values and the Abbott
assay using the CO1 and CO3 values. These results were prob-
ably due to the low CO values that were used that gave high
false positive results or to the inability of the DBS assay to detect
HCV AgAb in the samples whose paired sera samples presented
low OD values. The present study has documented HCV AgAb
detection among DBS samples that can be helpful in identify-
ing individuals at the window period of HCV infection in remote
areas.
Regarding DBS stability for HCV AgAb detection, it was possible
to obtain accurate results for up to 60 days when the DBS sam-
ples were stored in three different conditions (2–8 ◦C, 20–25 ◦C
and −20 ◦C). The same effect was  observed for anti-HCV detec-
tion among the DBS samples in a previous study, and this stability
was  higher than that reported by Tuaillon et al. in which the sam-
ples were stable for 2–12 days before being stored at −20 ◦C.12 In
this study, −20 ◦C was  the optimum storage condition for extended
periods of storage.
Using an optimised assay, a low limit of detection and CV values
were observed in the repetitivity and reproducibility studies, which
demonstrates the feasibility of the method.
DBS samples can be used for HCV AgAb detection using com-
mercial EIAs, and the Bio-Rad EIA showed the best performance.
DBS samples present great stability because HCV AgAb could be
detected for two months at three conditions (2–8 ◦C, 20–25 ◦C and
−20 ◦C). This method may  represent an alternative method for HCV
AgAb detection and can overcome the difﬁculties of blood samp-
ling and management, as evidenced in the screening analysis. This
102 C.P.U. Brandão et al. / Journal of Clinical Virology 57 (2013) 98– 102
Table 5
Repetitivity and reproducibility studies for two enzyme immunoassays (EIAs) used for HCVAgAb detection among dried blood spot (DBS) samples with high (101) and low
viral  titres (103).
HCV AgAb titre (estimated IU/mL) Observed optical density of EIA
Repetitivity study Reproducibility study
Murex HCV AgAb
combination EIA (Abbott)
Mean ± SD/CV (%)
MonolisaTM HCV AgAb
ULTRA EIA (Biorad)
Mean ± SD/CV (%)
Murex HCV  AgAb
combination EIA (Abbott)
Mean ± SD/CV (%)
MonolisaTM HCV AgAb
ULTRA EIA (Biorad)
Mean ± SD/CV (%)
High titre (310) 3.000 ± 0.000/0.0 2.136 ± 0.059/2.8 2.832 ± 0.189/6.7 2.259 ± 0.090/4.0
3 ± 0.
E
m
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i
p
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R
R
1
1
1
1
1
1
1
1
1
1
2
2
2Low  titre (3.1) 0.466 ± 0.016/3.5 0.45
IA: enzyme immunoassay; SD: standard deviation; CV: coefﬁcient of variation.
ethod may  be especially useful for HCV AgAb detection for indi-
iduals living in areas with limited resources.
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